Industry-Provided Assets

Assets in this table are alphabetized by mechanism of action. These compounds and biologics have undergone significant preclinical and safety testing in humans.

2020 Table of Assets 

Code Number & Link to More Information

Mechanism
of Action

Original Development Indication(s)

Route of Administration Formulation Available
(CNS Penetrant+)

AZD1656 (PDF - 136KB)

Glucokinase (GK) activator

Type 2 Diabetes

Oral
(No/Low CNS)

AZD5213 (PDF - 136KB)

Histamine receptor 3 (H3) antagonist (inverse agonist)

Neuro

Oral
(CNS)

AZD5904 (PDF - 128KB)

Myeloperoxidase (MPO) inhibitor

Multiple sclerosis (MS), and Chronic obstructive pulmonary disease (COPD)

Oral
(No/Low CNS)

ZD4054 (PDF - 89KB)
zibotentan

Endothelin type A (ETA) antagonist

Oncology

Oral
(Low CNS)

PF-04995274 (PDF - 138KB)

5-Hydroxytryptamine 4 receptor (5-HT4) partial agonist

Gastroesophageal reflux disease

Alzheimer's disease

Oral
(Yes)

CE-224535 (PDF - 203KB)

Purinergic receptor 2 antagonist

Rheumatoid arthritis
Osteoarthritis

Oral

JNJ-18038683 (PDF - 67KB)

5-Hydroxytryptamine 7 receptor (5-HT7) antagonist

Major depressive disorder

Oral
(Yes)

JNJ-39269646 (PDF - 34KB)

Fast dissociating D2/D3/5-HT6 antagonist

Schizophrenia
Bipolar depression

Oral
(Yes)